A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)

Endo Pharmaceuticals15 enrolled

Overview

The purpose of this study is to observe and describe the effectiveness and local tolerability of intravesical treatment with valrubicin for non-muscle invasive bladder cancer (NMIBC) in a cohort of subjects treated under routine practice conditions.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Bladder Cancer CIS

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Males and females 18 years of age and older * Diagnosed with NMIBC * Prescribed intravesical valrubicin to treat NMIBC * Understood and signed Informed Consent to participate Exclusion Criteria: * None

Locations (11)

BCG Oncology

Phoenix, Arizona, United States

Urology Research Network

Hialeah, Florida, United States

Advanced Urology Association of Florida

Vero Beach, Florida, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.